A citation-based method for searching scientific literature

J M van Berge Henegouwen, M Jebbink, L R Hoes, H van der Wijngaart, L J Zeverijn, D L van der Velden, P Roepman, W W J de Leng, A M L Jansen, E van Werkhoven, V van der Noort, A J van der Wekken, A J de Langen, E E Voest, H M W Verheul, E F Smit, H Gelderblom. Eur J Cancer 2022
Times Cited: 1







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


HER2 Amplification and HER2 Mutation Are Distinct Molecular Targets in Lung Cancers.
Bob T Li, Dara S Ross, Dara L Aisner, Jamie E Chaft, Meier Hsu, Severine L Kako, Mark G Kris, Marileila Varella-Garcia, Maria E Arcila. J Thorac Oncol 2016
159
100


Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity.
Jacqulyne P Robichaux, Yasir Y Elamin, R S K Vijayan, Monique B Nilsson, Lemei Hu, Junqin He, Fahao Zhang, Marlese Pisegna, Alissa Poteete, Huiying Sun,[...]. Cancer Cell 2019
90
100

Pyrotinib in Patients with HER2-Amplified Advanced Non-Small Cell Lung Cancer: A Prospective, Multicenter, Single-Arm Trial.
Zhengbo Song, Dongqing Lv, Shi-Qing Chen, Jianjin Huang, Yuping Li, Shenpeng Ying, Xiaoyu Wu, Feng Hua, Wenxian Wang, Chunwei Xu,[...]. Clin Cancer Res 2022
14
100

Treatment efficacy of HER2-mutant lung adenocarcinoma by immune checkpoint inhibitors: a multicenter retrospective study.
Xiangling Chu, Huiping Qiang, Mengqing Xie, Xing Li, Jing Zhao, Yan Wu, Juan Zhou, Jinyan Ye, Chao Zhao, Chaonan Han,[...]. Cancer Immunol Immunother 2022
2
100

Expression and Clinical Significance of HER2 Gene and DNMT1 in Non-Small-Cell Lung Cancer.
Weiying Diao, Chenglong Ding, Boyang Yuan, Zan Li, Na Sun, Jiabin Huang. Dis Markers 2022
1
100


Conformational Landscapes of HER2 Exon 20 Insertions Explain Their Sensitivity to Kinase Inhibitors in Lung Adenocarcinoma.
Shen Zhao, Wenfeng Fang, Hui Pan, Yunpeng Yang, Ying Liang, Lin Yang, Xiaorong Dong, Jianhua Zhan, Kai Wang, Li Zhang. J Thorac Oncol 2020
15
100

Ultra-deep next-generation sequencing of plasma cell-free DNA in patients with advanced lung cancers: results from the Actionable Genome Consortium.
B T Li, F Janku, B Jung, C Hou, K Madwani, R Alden, P Razavi, J S Reis-Filho, R Shen, J M Isbell,[...]. Ann Oncol 2019
83
100

Ado-Trastuzumab Emtansine for Patients With HER2-Mutant Lung Cancers: Results From a Phase II Basket Trial.
Bob T Li, Ronglai Shen, Darren Buonocore, Zachary T Olah, Ai Ni, Michelle S Ginsberg, Gary A Ulaner, Michael Offin, Daniel Feldman, Todd Hembrough,[...]. J Clin Oncol 2018
259
100

Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma.
Wenfeng Fang, Shen Zhao, Ying Liang, Yunpeng Yang, Lin Yang, Xiaorong Dong, Li Zhang, Yong Tang, Shoufeng Wang, Yang Yang,[...]. Oncologist 2020
23
100

Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer.
Shoichi Kuyama, Katsuyuki Hotta, Masahiro Tabata, Yoshihiko Segawa, Yoshiro Fujiwara, Nagio Takigawa, Katsuyuki Kiura, Hiroshi Ueoka, Kenji Eguchi, Mitsune Tanimoto. J Thorac Oncol 2008
40
100



Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations.
Shuo Yang, Yan Wang, Chao Zhao, Xuefei Li, Qian Liu, Shiqi Mao, Yiwei Liu, Xiaofei Yu, Wanying Wang, Qinrun Tian,[...]. Transl Lung Cancer Res 2021
6
100

HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers.
Bob T Li, Flavia Michelini, Sandra Misale, Emiliano Cocco, Laura Baldino, Yanyan Cai, Sophie Shifman, Hai-Yan Tu, Mackenzie L Myers, Chongrui Xu,[...]. Cancer Discov 2020
82
100

Acquired Mechanisms of Resistance to Osimertinib-The Next Challenge.
Alejandro Ríos-Hoyo, Laura Moliner, Edurne Arriola. Cancers (Basel) 2022
3
100

Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
J Mazieres, A Drilon, A Lusque, L Mhanna, A B Cortot, L Mezquita, A A Thai, C Mascaux, S Couraud, R Veillon,[...]. Ann Oncol 2019
507
100

HER2 mutation and response to trastuzumab therapy in non-small-cell lung cancer.
Federico Cappuzzo, Lynne Bemis, Marileila Varella-Garcia. N Engl J Med 2006
174
100


Targeted therapy in NSCLC driven by HER2 insertions.
Solange Peters, Stefan Zimmermann. Transl Lung Cancer Res 2014
48
100

Daily Practice Assessment of KRAS Status in NSCLC Patients: A New Challenge for the Thoracic Pathologist Is Right around the Corner.
Christophe Bontoux, Véronique Hofman, Patrick Brest, Marius Ilié, Baharia Mograbi, Paul Hofman. Cancers (Basel) 2022
3
100

EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization.
Kathryn M Ferguson, Mitchell B Berger, Jeannine M Mendrola, Hyun Soo Cho, Daniel J Leahy, Mark A Lemmon. Mol Cell 2003
543
100

Randomized Phase II Trial of Carboplatin-Paclitaxel Versus Carboplatin-Paclitaxel-Trastuzumab in Uterine Serous Carcinomas That Overexpress Human Epidermal Growth Factor Receptor 2/neu.
Amanda N Fader, Dana M Roque, Eric Siegel, Natalia Buza, Pei Hui, Osama Abdelghany, Setsuko K Chambers, Angeles Alvarez Secord, Laura Havrilesky, David M O'Malley,[...]. J Clin Oncol 2018
206
100

The Potential of panHER Inhibition in Cancer.
Xiaochun Wang, Kathleen M Batty, Philip J Crowe, David Goldstein, Jia-Lin Yang. Front Oncol 2015
29
100

Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors.
Junji Tsurutani, Hiroji Iwata, Ian Krop, Pasi A Jänne, Toshihiko Doi, Shunji Takahashi, Haeseong Park, Charles Redfern, Kenji Tamura, Trisha M Wise-Draper,[...]. Cancer Discov 2020
127
100

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.
Yung-Jue Bang, Eric Van Cutsem, Andrea Feyereislova, Hyun C Chung, Lin Shen, Akira Sawaki, Florian Lordick, Atsushi Ohtsu, Yasushi Omuro, Taroh Satoh,[...]. Lancet 2010
100

Lung adenocarcinoma with ERBB2 exon 20 insertions: Comutations and immunogenomic features related to chemoimmunotherapy.
Panwen Tian, Hao Zeng, Liyan Ji, Zhenyu Ding, Li Ren, Wen Gao, Zaiwen Fan, Lin Li, Xiuning Le, Pansong Li,[...]. Lung Cancer 2021
4
100

Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas.
F R Hirsch, M Varella-Garcia, W A Franklin, R Veve, L Chen, B Helfrich, C Zeng, A Baron, P A Bunn. Br J Cancer 2002
179
100

HER2 Transmembrane Domain (TMD) Mutations (V659/G660) That Stabilize Homo- and Heterodimerization Are Rare Oncogenic Drivers in Lung Adenocarcinoma That Respond to Afatinib.
Sai-Hong Ignatius Ou, Alexa B Schrock, Eduard V Bocharov, Samuel J Klempner, Carolina Kawamura Haddad, Gary Steinecker, Melissa Johnson, Barbara J Gitlitz, Jon Chung, Paulo V Campregher,[...]. J Thorac Oncol 2017
59
100

Activity of a novel HER2 inhibitor, poziotinib, for HER2 exon 20 mutations in lung cancer and mechanism of acquired resistance: An in vitro study.
Takamasa Koga, Yoshihisa Kobayashi, Kenji Tomizawa, Kenichi Suda, Takayuki Kosaka, Yuichi Sesumi, Toshio Fujino, Masaya Nishino, Shuta Ohara, Masato Chiba,[...]. Lung Cancer 2018
43
100

NSCLC and HER2: between lights and shadows.
Giuseppina Rosaria Rita Ricciardi, Alessandro Russo, Tindara Franchina, Giuseppa Ferraro, Mariangela Zanghì, Antonio Picone, Antonino Scimone, Vincenzo Adamo. J Thorac Oncol 2014
49
100

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Heidi Greulich, Bethany Kaplan, Philipp Mertins, Tzu-Hsiu Chen, Kumiko E Tanaka, Cai-Hong Yun, Xiaohong Zhang, Se-Hoon Lee, Jeonghee Cho, Lauren Ambrogio,[...]. Proc Natl Acad Sci U S A 2012
200
100

Efficacy of Immune Checkpoint Inhibitors Alone or in Combination With Chemotherapy in NSCLC Harboring ERBB2 Mutations.
Felix C Saalfeld, Carina Wenzel, Petros Christopoulos, Sabine Merkelbach-Bruse, Timm M Reissig, Silke Laßmann, Sebastian Thiel, Jan A Stratmann, Ralf Marienfeld, Johannes Berger,[...]. J Thorac Oncol 2021
13
100

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.
Alice T Shaw, Dong-Wan Kim, Kazuhiko Nakagawa, Takashi Seto, Lucio Crinó, Myung-Ju Ahn, Tommaso De Pas, Benjamin Besse, Benjamin J Solomon, Fiona Blackhall,[...]. N Engl J Med 2013
100

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1.
Yusuke Ogitani, Tetsuo Aida, Katsunobu Hagihara, Junko Yamaguchi, Chiaki Ishii, Naoya Harada, Masako Soma, Hiromi Okamoto, Masataka Oitate, Shingo Arakawa,[...]. Clin Cancer Res 2016
354
100

Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors.
M G Kris, D R Camidge, G Giaccone, T Hida, B T Li, J O'Connell, I Taylor, H Zhang, M E Arcila, Z Goldberg,[...]. Ann Oncol 2015
202
100

Activity of Afatinib in Heavily Pretreated Patients With ERBB2 Mutation-Positive Advanced NSCLC: Findings From a Global Named Patient Use Program.
Solange Peters, Alessandra Curioni-Fontecedro, Hovav Nechushtan, Jin-Yuan Shih, Wei-Yu Liao, Oliver Gautschi, Vito Spataro, Mojca Unk, James Chih-Hsin Yang, Robert M Lorence,[...]. J Thorac Oncol 2018
53
100

Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment.
Grit S Herter-Sprie, Heidi Greulich, Kwok-Kin Wong. Front Oncol 2013
59
100

HER kinase inhibition in patients with HER2- and HER3-mutant cancers.
David M Hyman, Sarina A Piha-Paul, Helen Won, Jordi Rodon, Cristina Saura, Geoffrey I Shapiro, Dejan Juric, David I Quinn, Victor Moreno, Bernard Doger,[...]. Nature 2018
424
100

Fusion-positive non-small cell lung carcinoma: Biological principles, clinical practice, and diagnostic implications.
Daniel Kazdal, Véronique Hofman, Petros Christopoulos, Marius Ilié, Albrecht Stenzinger, Paul Hofman. Genes Chromosomes Cancer 2022
11
100

Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
J Mazières, F Barlesi, T Filleron, B Besse, I Monnet, M Beau-Faller, S Peters, E Dansin, M Früh, M Pless,[...]. Ann Oncol 2016
197
100

Setting Up an Ultra-Fast Next-Generation Sequencing Approach as Reflex Testing at Diagnosis of Non-Squamous Non-Small Cell Lung Cancer; Experience of a Single Center (LPCE, Nice, France).
Marius Ilié, Véronique Hofman, Christophe Bontoux, Simon Heeke, Virginie Lespinet-Fabre, Olivier Bordone, Sandra Lassalle, Salomé Lalvée, Virginie Tanga, Maryline Allegra,[...]. Cancers (Basel) 2022
3
100

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
Thomas J Lynch, Daphne W Bell, Raffaella Sordella, Sarada Gurubhagavatula, Ross A Okimoto, Brian W Brannigan, Patricia L Harris, Sara M Haserlat, Jeffrey G Supko, Frank G Haluska,[...]. N Engl J Med 2004
100

Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP).
Rafal Dziadziuszko, Egbert F Smit, Urania Dafni, Juergen Wolf, Bartosz Wasąg, Wojciech Biernat, Stephen P Finn, Roswitha Kammler, Zoi Tsourti, Manuela Rabaglio,[...]. J Thorac Oncol 2019
72
100

Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
Kangkook Lee, Hyun Ae Jung, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park, Myung-Ju Ahn. Cancer Res Treat 2020
13
100

Checkpoint Blockade in Lung Cancer With Driver Mutation: Choose the Road Wisely.
Antonio Calles, Jonathan W Riess, Julie R Brahmer. Am Soc Clin Oncol Educ Book 2020
41
100

Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
Michael Offin, Daniel Feldman, Ai Ni, Mackenzie L Myers, W Victoria Lai, Elena Pentsova, Adrienne Boire, Mariza Daras, Emmet J Jordan, David B Solit,[...]. Cancer 2019
34
100

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D J Slamon, B Leyland-Jones, S Shak, H Fuchs, V Paton, A Bajamonde, T Fleming, W Eiermann, J Wolter, M Pegram,[...]. N Engl J Med 2001
100

A Phase II Study of Trastuzumab Emtansine in HER2-Positive Non-Small Cell Lung Cancer.
Katsuyuki Hotta, Keisuke Aoe, Toshiyuki Kozuki, Kadoaki Ohashi, Kiichiro Ninomiya, Eiki Ichihara, Toshio Kubo, Takashi Ninomiya, Kenichi Chikamori, Daijiro Harada,[...]. J Thorac Oncol 2018
89
100


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.